Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
![]() |
![]() ![]() |
Ultima descărcare din IBN: 2023-08-08 14:18 |
Căutarea după subiecte similare conform CZU |
616.5-057:616-036.22:578.834.1 (1) |
Piele. Tegumente în general. Dermatologie clinică. Tulburări cutanate (211) |
Virologie (446) |
![]() . Acute febrile neutrophilic dermatosis, post COVID-19. Case presentation. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 3 An.1(29), p. 237. ISSN 2345-1467. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista de Ştiinţe ale Sănătăţii din Moldova | ||||||
Numărul 3 An.1(29) / 2022 / ISSN 2345-1467 | ||||||
|
||||||
CZU: 616.5-057:616-036.22:578.834.1 | ||||||
Pag. 237-237 | ||||||
|
||||||
![]() |
||||||
Rezumat | ||||||
Background. Acute febrile neutrophilic dermatosis, also called Sweet’s syndrome, is a rare condition, manifested by polymorphic erythema rash, accompanied by fever up to 40°C, neutrophilic leukocytosis. Often occurs after an acute respiratory infection. Objective of the study. Elucidation of the case of Sweet’s syndrome, it’s clinical and paraclinical diagnosis and the corresponding therapeutic conduct. Material and Methods. Anamnesis, clinical examination, and biological samples were evaluated. Results. A 60-year-old patient presented disseminated skin lesions in the cervical region, abdomen, back, upper and lower limbs, accompanied by a burning sensation, fever 38°C. The rash appeared after COVID 19, at about 2 weeks. Prior to hospitalization, he was treated with sol. dexamethasone 8 mg, with a positive effect, but the skin process recurred after stopping the treatment. At the time of hospitalization, there was third exacerbation. Dermatological status: papules and erythematous spots, some cockade injuries, well defined, infiltrated size 1-4 cm in diameter, pustules, some medium-sized blisters, positive phatergy test. Paraclinical: neutrophilia, increased ESR. Treatment: prednisolone 0.7 mg/kg/day, doxycycline 200 mg/ day. The rash improved significantly in 7 days, was recommended to continue the prescribed treatment, tapering the dose until stopping. Conclusion. Sweet’s syndrome, diagnosed in a post-COVID-19 patient, had specific manifestations of the underlying basic syndrome, recurrent aspect, which regressed under prolonged corticosteroid therapy. |
||||||
Cuvinte-cheie Acute febrile neutrophilic dermatosis, Sweet’s syndrome, COVID-19, corticosteroid therapy, Dermatoza acută neutrofilică febrilă, sindrom Sweet, COVID-19, corticoterapie |
||||||
|